Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
A 47-year-old woman with branch retinal arterial occlusion treated with sodium ozagrel is described. The patient presented with acute visual field loss in her right eye. Blood tests demonstrated the elevation of beta-thromboglobulin and platelet factor 4. Sodium ozagrel, a thromboxane A2 synthetase inhibitor, 160 mg daily was administered for 14 days. This treatment prevented exacerbation of retinal arterial thrombosis and produced a marked improvement in the visual field loss. Sodium ozagrel may be a useful drug in the treatment of acute retinal arterial occlusion thought to be caused by thrombosis.
Kato
H
H
Department of Internal Medicine, Saga Medical School, Japan.
Emura
S
S
Takeuchi
N
N
Enoki
M
M
Oogushi
K
K
Takashima
T
T
Ohmori
K
K
Saito
I
I
D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008689:Methacrylates / Q000627:therapeutic use*; D008875:Middle Aged; D015356:Retinal Artery Occlusion / Q000188:drug therapy*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014794:Visual Fields / Q000187:drug effects
D004791:Enzyme Inhibitors; D008689:Methacrylates; D013930:Thromboxane-A Synthase; C034364:ozagrel